RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX)

RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX) Jeff Lewis Thu, June 4, 2026 at 6:49 PM GMT+2 2 min read NBIX Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the 15 Most Promising Stocks to Buy Right Now . On May 29, 2026, RBC Capital raised the firm’s price target on Neurocrine Biosciences, Inc.

(NASDAQ:NBIX) to $183 from $180 and maintained an Outperform rating on the shares. RBC said the stock has rebounded after a strong Q1, though concerns remain that Crenessity uptake could hit a near-term ceiling. RBC also said its endocrinologist survey suggests room for near- and long-term growth, including expected utilization growth among doctors not currently using the drug.

On May 21, 2026, Bernstein analyst Jeffrey Walch initiated coverage of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) with an Outperform rating and a $221 price target. Walch described Neurocrine as one of the more promising names in Bernstein’s initial coverage group of mid-cap biopharmaceutical companies, noting that the company’s two key medicines are already approved and have a long runway until loss-of-exclusivity.

Bernstein added that upside could come as the market gains more certainty around future market share and a Phase 3 trial readout. RBC Capital Raises its Price Target on Neurocrine Biosciences (NBIX) create jobs 51/Shutterstock. com Earlier in May, Neurocrine Biosciences, Inc.

(NASDAQ:NBIX) reported Q1 adjusted EPS of $1. 94, ahead of the consensus estimate of $1. 70.

Revenue totaled $811M, above the consensus estimate of $767. 88M. CEO Kyle Gano said the quarter reflected “continued momentum” across the commercial portfolio, with net product sales up 44% year-over-year, driven by demand for INGREZZA and CRENESSITY.

Gano also cited the agreement to acquire Soleno Therapeutics and the company’s pipeline. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) discovers, develops, and commercializes pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.

While we acknowledge the potential of NBIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the   best short-term AI stock . READ NEXT:  33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy .

  Disclosure: None. Follow Insider Monkey on Google News .